Treatment of Retinal Pigment Epithelial Detachment
International Journal of Clinical and Experimental Ophthalmology
Anatomical separation of the retinal pigment epithelium from the Bruch membrane is defi ned as retinal pigment epithelial detachment (PED) andit is classifi ed as drusenoid, serous, and vascularized. Vascularized PED is mostly associated with choroidal neovascularmembrane due to age-related macular degeneration and the risk of vision loss is high in this situation. Studies show that all of baseline values including BCVA, PED height, subretinal fl uid, central macular thickness, PED volume,
... cal dimension, presence of coincident macular pathology, refl ectivity and morphology on optical coherence tomography have prognostic importance. Current treatment protocols mainly based on intravitreal injection of anti-vascular endothelial growth factor (VEGF). Even the bevacizumab was the fi rst anti-VEGF that was used for treatment in PED, there are several reports show the insuffi ciency of bevacizumab. In treatment-naïve eyes, both of ranibizumab and afl ibercepthave similar effect in vascularized PED. In treatment-resistant eyes, high dose bevacizumab or switching therapy of anti-VEGF procedures can be effective when considering of all cases, afl ibercept seems more effective than other options.We aimed in this manuscript, to give a general information about different characteristics of PEDs and to investigate the treatment strategies in the light of current literature.